A record of what Siddhartha Khemka said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the Pharma sector, viewing recent corrections as a buying opportunity. The sector is expected to report a strong 15% earnings growth for the sixth consecutive quarter, outperforming the flattish Nifty earnings. Cipla, Divi’s, Ipca Labs, and Mankind are preferred picks due to strong expected numbers.”
Nifty PharmaBullishCalled 11 Oct 2024
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Siddhartha Khemka’s full track record